In the APOLLO trial, first-line treatment with anlotinib plus penpulimab improved progression-free survival and overall survival when compared to sorafenib.

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.

Researchers conducted a concept analysis of processing speed in relation to the cognitive function of patients with cancer.